Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Clinical trial NCT04668300 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04668300
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Angiosarcoma Metastatic Dedifferentiated Liposarcoma Metastatic Osteosarcoma Recurrent Angiosarcoma Recurrent Dedifferentiated Liposarcoma Recurrent Osteosarcoma Refractory Dedifferentiated Liposarcoma Refractory Osteosarcoma

Start date: 2020-11-26
Primary completion: 2027-06-30
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.